Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder ...

Vertex's chief executive, Reshma Kewalramani. Vertex Pharma's bid to expand beyond its cystic fibrosis franchise has taken a big step forward, thanks to positive late-stage clinical data for ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

March 9 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage ‌trial, putting the company on ...

I’ve had my Shark Rocket HV301 for seven years, and it has never let me down on hardwood floors, high-pile area rugs, or tile. Recently, I moved into a larger apartment with more furniture, more ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Vertex Pharmaceuticals' strategy is to develop medicines in areas with high unmet needs. The company has dominated the market for cystic fibrosis (CF) -- a rare disease that affects internal organs -- ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...